RXII - RXi Pharmaceuticals Corporation

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Income Statement
Balance Sheet
Cash Flow

Income Statement

All numbers in thousands
Total Revenue193471
Cost of Revenue---
Gross Profit193471
Operating Expenses
Research Development5,4156,9255,680
Selling General and Administrative3,6193,3463,217
Non Recurring---
Total Operating Expenses---
Operating Income or Loss-9,015-10,237-8,826
Income from Continuing Operations
Total Other Income/Expenses Net211426
Earnings Before Interest and Taxes-8,994-10,223-8,800
Interest Expense---
Income Before Tax-8,994-10,223-8,800
Income Tax Expense---
Minority Interest---
Net Income From Continuing Ops-8,994-10,223-8,800
Non-recurring Events
Discontinued Operations---
Extraordinary Items---
Effect Of Accounting Changes---
Other Items---
Net Income
Net Income-8,994-10,223-8,800
Preferred Stock And Other Adjustments---
Net Income Applicable To Common Shares-11,069-10,432-12,930